Genomic Valley Biotech Stock Screener | Share Price & Fundamental Analysis
GVBL
Biotechnology
Screen Genomic Valley Biotech share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price BSE
₹25.16
▼
-0.70 (-2.71%)
Market Cap
₹7.58 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
1.85
EPS (TTM)
₹1.17
Dividend Yield
-
Debt to Equity
-
52W High
₹90.12
52W Low
₹21.85
Operating Margin
27.00%
Profit Margin
-
Revenue (TTM)
₹1.00
EBITDA
-
Net Income
-
Total Assets
₹4.00
Total Equity
₹4.00
Genomic Valley Biotech Share Price History - Stock Screener Chart
Screen GVBL historical share price movements with interactive charts. Analyze price trends and patterns.
Genomic Valley Biotech Company Profile - Fundamental Screener
Screen Genomic Valley Biotech company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for GVBL shares.
Sector
Healthcare
Industry
Biotechnology
Sub-Sector
Biotechnology
Segment
E
ISIN
INE574D01010
Genomic Valley Biotech Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen GVBL balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 4 | 4 | 4 | 4 | 8 | 8 | 7 | 7 | 6 | 6 |
| Current Assets | 3 | 3 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 0 | 0 | 0 | 2 | 6 | 5 | 4 | 4 | 4 | 3 |
| Liabilities | ||||||||||
| Total Liabilities | 4 | 4 | 4 | 4 | 8 | 8 | 7 | 7 | 6 | 6 |
| Current Liabilities | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 1 | 1 | 1 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 4 | 4 | 4 | 3 | 5 | 5 | 5 | 5 | 5 | 5 |
| Share Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves & Surplus | 1 | 1 | 1 | 0 | 1 | 2 | 2 | 2 | 1 | 2 |
Screen GVBL income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | None-None | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1 | 1 | 0 | 3 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 |
| Expenses | 1 | 0 | 0 | 2 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 0 |
| EBITDA | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Operating Profit % | 27.00% | 52.00% | 9.00% | 32.00% | -535.00% | -66.00% | 65.00% | 42.00% | 17.00% | -23.00% | -422.00% | -249.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 0 | 0 | 0 | 1 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Profit | 0 | 0 | 0 | 1 | 0 | -1 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS | 0.30 | 1.17 | 0.05 | 2.12 | -0.03 | -1.83 | 0.94 | 0.76 | 0.11 | -0.22 | -1.10 | -0.03 |
Genomic Valley Biotech Cash Flow Screener - Liquidity Fundamentals
Screen GVBL cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 0 | 0 | -1 | -2 | 2 | 0 | -1 | 1 | 0 | -1 |
| Investing Activities | 0 | 0 | 2 | 4 | -2 | -1 | 0 | -1 | 0 | 1 |
| Financing Activities | 0 | 0 | -1 | -2 | 0 | 0 | 1 | 0 | 0 | 0 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Screen GVBL shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 46.78% | 46.72% | 46.72% | 64.20% | 64.14% | 54.67% | 46.83% | 67.18% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 52.62% | 52.79% | 52.53% | 34.45% | 35.06% | 44.74% | 52.59% | 32.17% |
| Other Holding | 0.60% | 0.49% | 0.76% | 1.35% | 0.81% | 0.59% | 0.58% | 0.65% |
| Shareholder Count | 2,504 | 2,460 | 2,459 | 1,334 | 1,540 | 2,128 | 2,497 | 380 |
Genomic Valley Biotech Dividend Screener - Share Yield Analysis
Screen GVBL dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
Genomic Valley Biotech Index Membership - Market Screener Classification
Screen GVBL by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Genomic Valley Biotech Market Events Screener - Corporate Actions
Screen GVBL market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-12-31 | 2026-12-31 | Annual General Meeting | NA | -13.64% |
| 2025-12-30 | 2025-12-30 | Annual General Meeting | NA | -18.30% |
| 2025-10-15 | 2025-10-15 | Quarterly Result Announcement | NA | 0.19% |
| 2025-08-07 | 2025-08-07 | Quarterly Result Announcement | NA | -2.15% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | -11.44% |
| 2025-02-14 | 2025-02-14 | Quarterly Result Announcement | NA | 14.40% |
| 2024-10-07 | 2024-10-07 | Quarterly Result Announcement | NA | 0.12% |
Genomic Valley Biotech Competitors Screener - Peer Comparison
Screen GVBL competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Anthem Biosciences | 35,912 | 69.82 | 1,930 | 30.15% | 451 | 39.02 |
| Advanced Enzyme Tech | 3,355 | 21.48 | 670 | 1.44% | 134 | 43.45 |
| Genesis IBRC | 111 | -501.11 | 4 | % | 0 | 23.78 |
| Vivo Bio Tech | 70 | 17.36 | 52 | 13.19% | 7 | 54.81 |
| Shree Ganesh Bio-Tech | 24 | 24 | 14.55% | 0 | 40.20 | |
| Genomic Valley Biotech | 8 | 72.15 | 1 | 300.00% | 0 | 46.59 |
Genomic Valley Biotech Company Announcements - News Screener
Screen GVBL latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-07 | Closure of Trading Window | View |
| 2025-12-10 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-12-09 | Notice Of The Annual General Meeting | View |
| 2025-12-09 | Reg. 34 (1) Annual Report. | View |
| 2025-12-08 | Book Closure Intimation | View |
| 2025-12-08 | Board Meeting Outcome for Outcome Of The Board Meeting Dated 08-12-2025 | View |
| 2025-10-17 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-10-15 | Un-Audited Standalone Financial Results For The Quarter And Half Yearly Ended On September 30Th 2025 | View |
| 2025-10-15 | Board Meeting Outcome for Outcome Of Board Meeting Pursuant To Regulation 30 Of Sebi (LODR)Regulation 2015 Held On Today I.E. 15Th October 2025 | View |
| 2025-10-10 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-10-07 | Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015 | View |
| 2025-09-26 | Closure of Trading Window | View |
| 2025-09-04 | Intimation Of Approval Of Extension Of Time For Holding Annual General Meeting (AGM) Of The Company For The Financial Year Ended On 31St March 2025 Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | View |
| 2025-08-09 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-08-07 | Re-Appointment Of Mr. Yogesh Agrawal As Chairman & Managing Director Of The Company For The Period Of Five (5) Years With Effect From 07.09.2025 | View |
| 2025-08-07 | Appointment Of Internal Auditor For The FY 2025-26. | View |
| 2025-08-07 | Appointment Of Secretarial Auditor | View |
| 2025-08-07 | Unaudited Financial Results For Quarter Ended June 30 2025. | View |
| 2025-08-07 | Board Meeting Outcome for Outcome Of The Board Meeting Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Held On Today I.E. 07Th August 2025 | View |
| 2025-07-29 | Board Meeting Intimation for Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | View |